In today's interview, we have the pleasure of speaking with Ivan Kairatov, a biopharma expert renowned for his expertise in technology and innovation within the industry. With extensive experience in research and development, Ivan provides invaluable insights into the current challenges and
Ivan Kairatov is a renowned expert in the biopharma industry, particularly in the realms of technology and innovation. His expertise in research and development has helped shape advancements in targeted cancer therapies. We discuss the recent FDA approval of the tablet formulation of Brukinsa, a
Breast cancer remains the leading cancer diagnosis in women globally, presenting significant challenges due to its heterogeneity and biological complexity. This diversity in tumor types and characteristics demands innovative therapeutic approaches beyond traditional treatments. In recent years,
Cancer treatment, long considered a formidable challenge, has seen significant advancements with the collaboration of engineering and biomedical sciences. The Cancer Bioengineering Collaborative represents a milestone in merging these disciplines to revolutionize cancer diagnosis, monitoring, and
Imagine facing the battle against a form of lung cancer so rare that it affects only about 2% of those diagnosed with non-small cell lung cancer (NSCLC). This is the reality for those with ROS1-positive NSCLC, a disease that could soon see transformative change with the approval of Nuvation Bio's
Imagine facing a life-threatening illness only to find that your race determines the quality of treatment you receive. This scenario, unthinkable to many, is a stark reality for individuals battling metastatic prostate cancer. However, recent groundbreaking research offers new avenues to overcome
